awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q28077245-6064AE0C-8D3C-4560-B093-7FC9FF0E6979
Q28077245-6064AE0C-8D3C-4560-B093-7FC9FF0E6979
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28077245-6064AE0C-8D3C-4560-B093-7FC9FF0E6979
Antiestrogens: structure-activity relationships and use in breast cancer treatment
P2860
Q28077245-6064AE0C-8D3C-4560-B093-7FC9FF0E6979
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28077245-6064AE0C-8D3C-4560-B093-7FC9FF0E6979
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
6fd755f2b14e472894810fd8f9dfa58c833489c4
P2860
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.